Wells Fargo lowered the firm’s price target on Fate Therapeutics (FATE) to $4 from $5 and keeps an Equal Weight rating on the shares. The firm continues to think Fate’s main opportunity is in autoimmune diseases, and awaits visibility for next data readout from FT819’s SLE study. Wells also highlights the recent protocol amendment to include additional autoimmune indications as interesting development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties
- Fate Therapeutics Advances CAR T-cell Programs Amid Financial Losses
- Fate Therapeutics reports Q4 EPS (44c), consensus (42c)
- FATE Earnings this Week: How Will it Perform?
- Biotech Alert: Searches spiking for these stocks today